SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

Bo Feldt-Rasmussen; Rikke Borg; Jan Carstens; Ditte Hansen; Mads Hornum; Morten Lindhardt; Frank Holden Mose; Birgitte Bang Pedersen; Johan Vestergaard Poulsen; Kristine Dyhr Schandorff; Charlotte Strandhave

SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

Translated title of the contribution: SGLT2 inhibitorsfor treatment of chronic kidney disease without diabetes or heart failure

Bo Feldt-Rasmussen, Rikke Borg^*, Jan Carstens, Ditte Hansen, Mads Hornum, Morten Lindhardt, Frank Holden Mose, Birgitte Bang Pedersen, Johan Vestergaard Poulsen, Kristine Dyhr Schandorff, Charlotte Strandhave

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

11 Downloads (Pure)

Abstract

This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.

Translated title of the contribution	SGLT2 inhibitorsfor treatment of chronic kidney disease without diabetes or heart failure
Original language	Danish
Article number	V11210887
Journal	Ugeskift for Læger
Volume	184
Issue number	20
Pages (from-to)	1872-1875
Number of pages	4
ISSN	0041-5782
Publication status	Published - 18 Apr 2022

Access to Document

Feldt-Rasmussen et al. (2022). SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigtFinal published version, 444 KBLicence: CC BY-NC-ND 4.0

https://ugeskriftet.dk/videnskab/sglt2-haemning-til-kronisk-nyresygdom-uden-ledsagende-diabetes-eller-hjertesvigtLicence: CC BY-NC-ND 4.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Feldt-Rasmussen, B., Borg, R., Carstens, J., Hansen, D., Hornum, M., Lindhardt, M., Mose, F. H., Pedersen, B. B., Poulsen, J. V., Schandorff, K. D., & Strandhave, C. (2022). SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt. Ugeskift for Læger, 184(20), 1872-1875. Article V11210887. https://ugeskriftet.dk/videnskab/sglt2-haemning-til-kronisk-nyresygdom-uden-ledsagende-diabetes-eller-hjertesvigt

@article{54d666b445e74f88ad5eb53e24ec371a,

title = "SGLT2-h{\ae}mning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt",

abstract = "This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.",

keywords = "Diabetes Mellitus, Electroconvulsive Therapy/adverse effects, Female, Heart Failure/drug therapy, Humans, Male, Renal Insufficiency, Chronic/complications, Sodium-Glucose Transporter 2",

author = "Bo Feldt-Rasmussen and Rikke Borg and Jan Carstens and Ditte Hansen and Mads Hornum and Morten Lindhardt and Mose, {Frank Holden} and Pedersen, {Birgitte Bang} and Poulsen, {Johan Vestergaard} and Schandorff, {Kristine Dyhr} and Charlotte Strandhave",

year = "2022",

month = apr,

day = "18",

language = "Dansk",

volume = "184",

pages = "1872--1875",

journal = "Ugeskift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "20",

}

Feldt-Rasmussen, B, Borg, R, Carstens, J, Hansen, D, Hornum, M, Lindhardt, M, Mose, FH, Pedersen, BB, Poulsen, JV, Schandorff, KD & Strandhave, C 2022, 'SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt', Ugeskift for Læger, vol. 184, no. 20, V11210887, pp. 1872-1875. <https://ugeskriftet.dk/videnskab/sglt2-haemning-til-kronisk-nyresygdom-uden-ledsagende-diabetes-eller-hjertesvigt>

TY - JOUR

T1 - SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

AU - Feldt-Rasmussen, Bo

AU - Borg, Rikke

AU - Carstens, Jan

AU - Hansen, Ditte

AU - Hornum, Mads

AU - Lindhardt, Morten

AU - Mose, Frank Holden

AU - Pedersen, Birgitte Bang

AU - Poulsen, Johan Vestergaard

AU - Schandorff, Kristine Dyhr

AU - Strandhave, Charlotte

PY - 2022/4/18

Y1 - 2022/4/18

N2 - This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.

AB - This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.

KW - Diabetes Mellitus

KW - Electroconvulsive Therapy/adverse effects

KW - Female

KW - Heart Failure/drug therapy

KW - Humans

KW - Male

KW - Renal Insufficiency, Chronic/complications

KW - Sodium-Glucose Transporter 2

UR - http://www.scopus.com/inward/record.url?scp=85129780475&partnerID=8YFLogxK

M3 - Tidsskriftartikel

C2 - 35485777

SN - 0041-5782

VL - 184

SP - 1872

EP - 1875

JO - Ugeskift for Læger

JF - Ugeskift for Læger

IS - 20

M1 - V11210887

ER -

SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

Abstract

Access to Document

AUB Link

Other files and links

Fingerprint

Cite this